User login
Key clinical point: Nanoparticle albumin‐bound (nab) paclitaxel showed promising clinical activity and tolerable safety in patients with metastatic breast cancer (BC) who were previously treated with taxanes, regardless of their sensitivity or resistance to taxane therapy.
Major finding: The median progression-free survival (PFS) was 7.20 months (95% CI 6.63-7.80 months) for all patients. The median PFS was significantly longer (7.57 vs 4.43 months; P < .001) and the disease control rate was 88.24% vs 68.00% in patients who were taxane-sensitive vs taxane-resistant. Neutropenia (21.19%), leukopenia (19.49%), and sensory neuropathy (6.36%) were the most frequent grade 3-4 adverse events.
Study details: Findings are from a retrospective study including 236 taxane-pretreated women with metastatic BC, of whom 184 were sensitive and 52 were resistant to taxanes based on previous treatment and received nab-paclitaxel as monotherapy or combination therapy.
Disclosures: This study was supported by the Jiangsu Provincial Medical Youth Talent and the Talents Program of Jiangsu Cancer Hospital, China. The authors declared no conflicts of interest.
Source: Xiong W, Xu T, Liu X, Zhang L, Yuan Y. Efficacy and safety of nanoparticle albumin-bound paclitaxel in taxane-pretreated metastatic breast cancer patients. Cancer. 2024 (Jan 25). doi: 10.1002/cncr.35206 Source
Key clinical point: Nanoparticle albumin‐bound (nab) paclitaxel showed promising clinical activity and tolerable safety in patients with metastatic breast cancer (BC) who were previously treated with taxanes, regardless of their sensitivity or resistance to taxane therapy.
Major finding: The median progression-free survival (PFS) was 7.20 months (95% CI 6.63-7.80 months) for all patients. The median PFS was significantly longer (7.57 vs 4.43 months; P < .001) and the disease control rate was 88.24% vs 68.00% in patients who were taxane-sensitive vs taxane-resistant. Neutropenia (21.19%), leukopenia (19.49%), and sensory neuropathy (6.36%) were the most frequent grade 3-4 adverse events.
Study details: Findings are from a retrospective study including 236 taxane-pretreated women with metastatic BC, of whom 184 were sensitive and 52 were resistant to taxanes based on previous treatment and received nab-paclitaxel as monotherapy or combination therapy.
Disclosures: This study was supported by the Jiangsu Provincial Medical Youth Talent and the Talents Program of Jiangsu Cancer Hospital, China. The authors declared no conflicts of interest.
Source: Xiong W, Xu T, Liu X, Zhang L, Yuan Y. Efficacy and safety of nanoparticle albumin-bound paclitaxel in taxane-pretreated metastatic breast cancer patients. Cancer. 2024 (Jan 25). doi: 10.1002/cncr.35206 Source
Key clinical point: Nanoparticle albumin‐bound (nab) paclitaxel showed promising clinical activity and tolerable safety in patients with metastatic breast cancer (BC) who were previously treated with taxanes, regardless of their sensitivity or resistance to taxane therapy.
Major finding: The median progression-free survival (PFS) was 7.20 months (95% CI 6.63-7.80 months) for all patients. The median PFS was significantly longer (7.57 vs 4.43 months; P < .001) and the disease control rate was 88.24% vs 68.00% in patients who were taxane-sensitive vs taxane-resistant. Neutropenia (21.19%), leukopenia (19.49%), and sensory neuropathy (6.36%) were the most frequent grade 3-4 adverse events.
Study details: Findings are from a retrospective study including 236 taxane-pretreated women with metastatic BC, of whom 184 were sensitive and 52 were resistant to taxanes based on previous treatment and received nab-paclitaxel as monotherapy or combination therapy.
Disclosures: This study was supported by the Jiangsu Provincial Medical Youth Talent and the Talents Program of Jiangsu Cancer Hospital, China. The authors declared no conflicts of interest.
Source: Xiong W, Xu T, Liu X, Zhang L, Yuan Y. Efficacy and safety of nanoparticle albumin-bound paclitaxel in taxane-pretreated metastatic breast cancer patients. Cancer. 2024 (Jan 25). doi: 10.1002/cncr.35206 Source